| **Study Reference** | **Participant Characteristics** | **Intervention; Duration** | **Discontinuations due to AE**  **Risk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **Serious AEs**  **Risk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **Gastrointestinal Adverse Eventsa**  **Risk in Treatment Group; Risk in Control Group**  **(RR [95% CI])** | **Other Adverse Events** | **Quality Rating** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Herd et al, 1997228 | Women 1-10 years postmenopausal; mean age 54.8 years; mean T-score -1.3; no prior fracture | Cyclical etidronate 400 mg/day; 2 years | 5/75; 0/77  [11.23 (0.64 to 200.68)] | 8/75; 7/77  [1.17 (0.44 to 3.07)] | GI AE events: 9/75; 17/77  [0.54 (0.26 to 1.14)] | Infection  18/74; 22/76  [0.84 (0.49 to 1.43)] | Fair |
| Meunier et al, 1997229 | Women 6-60 months postmenopausal; mean age 52.7 years; mean T-score -1.1; unknown prior fracture | Cyclical etidronate 400 mg/day; 2 years | 0/27; 2/27  [0.20 (0.01 to 3.98)] | NR | Severe GI  0/27; 0/27  RR not calculable  Mild abdominal pain  4/27; 1/27 (all had history of GI problems)  [4.00 (0.48 to 33.51)] | NR | Fair |

**Abbreviations:** AE=adverse event; CI=confidence interval; GI=gastrointestinal; mg=milligram; NR=not reported; RR=risk ratio.